Oellerich Lab
Mechanistic
Leukemia
Research
AG Oellerich
our focus
and mission
Mechanistic Cancer Research:
We combine innovative technologies such as proteomics, (functional) genomics, and molecular and cellular biology approaches to elucidate oncogenic mechanisms. To target these mechanisms, we additionally design and clinically validate innovative therapies. In lymphoma, we study the oncogenic pathways affecting B-cell receptor signaling, chromatin structure, and the tumor microenvironment. Additionally, in collaboration with Stefan Knapp (Dept. of Medicinal Chemistry, Frankfurt) we develop innovative drugs specifically targeting the newly identified oncogenic effector proteins. In AML, we currently focus on deregulated proteogenomic and metabolic programs and their therapeutic implications. More recently, we have expanded our mechanistic research program towards studying CAR-cell therapeutics with the goal to enhance their efficacy and to overcome resistance mechanisms.
Cell Therapy Research:
Clinical proteogenomics and systems biology:
We elucidate proteomic and genomic features and integrate them to identify, so far, unresolved aspects of tumor biology. The addition of single-cell sequencing analysis furthermore allows us to link observed patterns to individual tumor cells, or cells of the tumor microenvironment.
We have established the entire value chain, including relevant patient cohorts and clinical expertise, along with innovative proteomic and genomic technologies, IT infrastructure, as well as bioinformatics for integrative multi-modal data analysis. The goal of our proteogenomics research program is to further refine the molecular classification of tumors, to elucidate their pathophysiology, to identify biomarkers predicting therapy response, and to foster the development of innovative therapies.
Bioinformatics:
To fully leverage the comprehensive proteogenomic data that we are able to acquire from large patient cohorts, we collaborate closely with the lab of DKTK professor Florian Buettner (https://mlo-lab.github.io/author/florian-buettner). Together, we pursue the development and application of novel tools and algorithms for machine-learning and artificial intelligence based multi-omics data integration. We ensure that these tools are inherently interpretable, trustworthy, and are accompanied with user-friendly implementations in order to ensure broad applicability across diverse tumor entities.
Protein Interactome Profiling:
We have established a broad range of quantitative MS assays for the unbiased analysis of protein-protein interactions and their temporal dynamics. Our BioID/ Turbo-ID assays rely on the fusion of a protein of interest (bait) with a promiscuous biotin ligase enzyme, known as BirA*. Upon expression in living cells, this fusion protein biotinylates proximal proteins within a radius of 10-20 nanometers, covalently attaching biotin molecules to lysine residues. Subsequently, biotinylated proteins are isolated using streptavidin affinity purification, followed by elution and identification via mass spectrometry. By capturing proteins that come into close proximity with the bait protein, the BioID assay provides a comprehensive snapshot of the protein interactome within the cellular context.
Tissue/Blood Proteomics:
Proximity Ligation
Assays (PLA)
The proximity ligation assay is a well-established imaging methodology which allows us to evaluate the location and interaction of two specific protein targets in situ. In short, we are able to detect whether two proteins are within a certain proximity to each other (<40nm) and through quantification of fluorescent puncta upon confocal visualization, we can evaluate and quantify interaction differences upon specific treatments or genetic modifications.
Mass Spectrometry:
Currently, the platform is running four LC/MS systems (Thermo Fisher Scientific Q-Exactive series and Orbitrap Astral) and is fully equipped with state-of-the-art instrumentation for sample preparation and a powerful IT infrastructure. The available workflows for MS-based proteomics include global protein expression profiling of model systems and clinical samples, the analysis of post-translational modifications like phosphorylation or ubiquitination, as well as protein interaction studies. Typically, these are combined with isotopic labeling techniques (SILAC, TMT) or label-free approaches for relative protein quantitation. Moreover, the platform is open for the implementation of dedicated strategies required to promote specific projects of collaboration partners from the cancer research community. Thereby, interested DKTK/FCI researchers have full access to the platform services and receive project-specific advice.
The proteomics platform engages in the mechanistic elucidation of oncogenic processes, especially in the context of lymphoma and leukemia, but also colorectal cancer, glioma, breast cancer and lung cancer. Furthermore, the activities of the platform strongly focus on the systematic characterization of well-defined patient cohorts of these cancer entities, including trial cohorts and analyzing fresh-frozen as well as FFPE tissue samples and blood plasma. To this end, the achievements of the platform i) facilitate to identify proteomic disease subtypes with prognostic and predictive relevance in highly-collaborative multi-omics projects and ii) enable the allocation of proteomic workflows to DKTK/FCI investigators for their translational cancer research.
CRISPR-Cas9-based
functional genomics :
Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum.
Selected Technologies:
The proximity ligation assay is a well-established methodology in our laboratory that allows us to evaluate in situ the location and interaction of two specific protein targets. In short, we are able to detect whether two proteins are within a certain proximity to each other (<40nm) and through quantification of fluorescent puncta upon confocal visualization, we can then evaluate and quantify interaction differences upon specific treatments or genetic modifications
